12:00 – 1:00 pm EDT
The end of a long road has now been reached in AMP et al. v. Myriad et al. On June 12, in a unanimous decision, the Supreme Court of the United States declared patents for Myriad Genetics invalid. On its surface, the decision is relatively straightforward: “isolated DNA” composition claims are not patentable subject matter, while cDNA composition claims are. But is it really that straightforward? And what are the implications of the decision as it applies to other composition and method claims?
Please join our experienced panel as we examine the implications of the Supreme Court and Federal Circuit decisions in the case and how they may shape prosecution, partnering and litigation strategies in the life sciences.
William Gaede, Partner
Judy Mohr, Ph.D., Partner
Richard B. Smith, Partner
For more information, please contact McDermott Events.
CLE credit for the live presentation of this program is pending in the following states: California, Illinois, New York and Texas. A Uniform Certificate of Attendance will be made available to participants requesting CLE credit in all other states. Please be advised that CLE credit will not be approved for on demand/recorded viewings of this program in the states listed above. Attendees seeking credit in other states should consult their state CLE accrediting agency to determine whether self-study credit can be earned for on demand/recorded viewing of this program.